PDCD1 and prostate carcinoma: Although no differences were observed between treatment groups (Fig. 6B–G), for the CD3+ CD25+ cells (Fig. 6C), the majority were PD1+ (Fig. 6F), which is indicative of the regulatory T-cell (together in Fig. 6G) phenotype found in the bone-microenvironment of prostate cancer patients (16).